REGRESS – Regression Growth Evaluation Statin Study
Eric de Groot - Imagelabonline & Cardiovascular, Eindhoven and Lunteren, the Netherlands
The Regression Growth Evaluation Statin Study (REGRESS) is a two-arm clinical trial based at 11 centres in the Netherlands. The principal aim of the trial was to investigate the effect of Pravastatin (40mg/day) versus placebo on carotid and femoral artery walls. Men were eligible for inclusion if they were aged below 70 years with a serum cholesterol level between 4 and 8mmol/L and a serum triglyceride level ≤4.0 mmol/L. Written informed consent was obtained from all subjects. The study was approved by the Institutional Ethics Committees.
Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels: The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995 May 15;91(10):2528-40
B-Mode Ultrasound Assessment of Pravastatin Treatment Effect on Carotid and Femoral Artery Walls and Its Correlations With Coronary Arteriographic Findings: A Report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol. 1998 Jun;31(7):1561-7